August 30, 2016 12:12 AM ET

Pharmaceuticals

Company Overview of Solasia Pharma K.K.

Company Overview

Solasia Pharma K.K. engages in developing, marketing, and importing/exporting oncology products. It focuses on developing and commercializing assets in the oncology/hematology fields. The company also provides SP-01 Sancuso, a transdermal system that delivers the anti-emetic and granisetron into the patient’s bloodstream who cannot swallow medicines due to nausea or mucositis; and SP-02 Darinaparsin, a mitochondrial-targeted agent (organic arsenic) for the treatment of various hematologic and solid cancers. It serves customers in Japan, China, Hong Kong, Macau, Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, the Philippines, Thailand, and internationally. Solasia Pharm...

3rd Floor

Shiodome Building

1-2-20, Kaigan

Minato-ku

Tokyo,  105-0022

Japan

Founded in 2006

Phone:

81 3 6721 8332

Fax:

81 3 6721 2020

Key Executives for Solasia Pharma K.K.

President and Representative Director
Founder and External Director
Age: 49
Chief Financial Officer and Director
Head of Product Development Division
Head of Business Development Department
Compensation as of Fiscal Year 2016.

Solasia Pharma K.K. Key Developments

Solasia Pharma K.K. Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma

Solasia Pharma K.K. announced that an Asian Multinational Phase II study of SP-02 (darinaparsin) for injection (SP-02L) for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL) has commenced. This single-arm, open-label, non-randomized study is being conducted in Japan, South Korea, Taiwan and Hong Kong; to evaluate the efficacy and safety of SP-02L monotherapy. SP-02 is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid cancers. In a US Phase II study, SP-02 demonstrated clinical activity in lymphoma, in particular PTCL. In Phase I studies, in Japan and South Korea, safety and potential efficacy against PTCL have also been demonstrated. Based on the Phase II result, Solasia intends to file for registration in Japan, South Korea, Taiwan and Hong Kong. Solasia obtained an exclusive worldwide license to develop and commercialize SP-02 from ZIOPHARM Oncology Inc., and the company is currently conducting clinical trials in Japan and other parts of Asia. Solasia granted development and commercialization rights of SP-02 in Japan to Meiji Seika Pharma Co. Ltd.

Solasia Pharma Signs Exclusive License Agreement with Lee's Pharmaceutical

Solasia Pharma has signed an exclusive license agreement with Lee's Pharmaceutical Holdings. The contract has been signed for commercialisation and promotion of Sancuso (granisetron transdermal delivery system) in the People's Republic of China excluding Taiwan, Hong Kong, Macau and the Retained Territory. According to the terms of the contract, Solasia granted Lee's Pharma an exclusive license and right to promote, commercialise, distribute and sell Sancuso, an extended release transdermal system, in the licensed territory for patients suffering from chemotherapy-induced nausea vomiting. Solasia will retain rights to promote Sancuso in three major cities, including Beijing, Shanghai and Guangzhou, the 'Retained Territory', in the People's Republic of China.

Solasia Pharma K.K. and Lee’S Pharmaceutical Holdings Limited Announce License, Promotion and Supply Agreement for Sancuso

Solasia Pharma K.K. and Lee’s Pharmaceutical Holdings Limited jointly announced that Solasia and Lee’s Pharma have entered into an exclusive license agreement for the commercialization and promotion of Sancuso® (granisetron transdermal delivery system) in the People’s Republic of China excluding Taiwan, Hong Kong, Macau and the Retained Territory. Solasia will retain rights to promote Sancuso® in three major cities (Beijing, Shanghai and Guangzhou; the ‘Retained Territory’) in the PRC. Under the terms of the Agreement, Solasia granted Lee’s Pharma an exclusive license and right for promoting, commercializing, distributing and selling Sancuso® in the licensed territory for the patients suffering from chemotherapy-induced nausea vomiting (CINV) caused by chemotherapy. Solasia obtained an exclusive license to develop and commercialize Sancuso® for Asian territories from ProStrakan and is currently waiting for approval from the China Food and Drug Administration.

Similar Private Companies By Industry

Company Name Region
ABsize Inc. Asia
AccuRna, Inc. Asia
ACE Japan, L.L.C. Asia
AIP Corporation Asia
alphaGEN Co., Ltd. Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Solasia Pharma K.K., please visit www.solasia.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.